Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells by unknown
Cucurbitacin D induces cell cycle arrest and apoptosis
by inhibiting STAT3 and NF-jB signaling in doxorubicin-resistant
human breast carcinoma (MCF7/ADR) cells
Jin Mo Ku1 • Soon Re Kim1 • Se Hyang Hong1 • Han-Seok Choi1 •
Hye Sook Seo1 • Yong Cheol Shin1 • Seong-Gyu Ko1
Received: 28 April 2015 / Accepted: 4 July 2015 / Published online: 14 July 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Breast cancer is the most common cancer for
women and is a major cause of mortality in women.
Doxorubicin is a generally used chemotherapy drug for
breast cancer. However, multidrug resistance of breast
cancer interferes with the chemotherapy. We examined
whether cucurbitacin D affects doxorubicin resistance of
MCF7/ADR breast cancer cells. Cell viability was mea-
sured by MTT assay. Levels of p-STAT3, p-NF-jB, IjB,
and caspases were measured by Western blot analysis.
Nuclear staining of Stat3 and NF-jB was measured by
immunocytochemistry. STAT3 and NF-jB transcriptional
activity was detected by STAT3 and NF-jB luciferase
reporter gene assays. Analysis of cell cycle arrest was
performed by flow cytometry. Induction of apoptosis by
cucurbitacin D was measured by Annexin V-FITC/pro-
pidium iodide assay. More than 90 % of MCF7/ADR cells
lived upon treatment with doxorubicin for 24 h. However,
upon treatment with cucurbitacin D, cell death was more
than 60 %. Co-administration of cucurbitacin D and dox-
orubicin induced apoptosis, and G2/M cell cycle arrest, and
inhibited upregulated Stat3 by doxorubicin on MCF7/ADR
cells. Additionally, cucurbitacin D led to an increase in the
IjBa level in the cytosol and a decrease in the p-NF-jB
level in the nucleus. Finally, cucurbitacin D inhibited
translocation of Stat3 and NF-jB and decreased tran-
scriptional activity in the nucleus. Cucurbitacin D decrea-
ses cell proliferation and induces apoptosis by inhibiting
Stat3 and NF-jB signaling in doxorubicin-resistant breast
cancer cells. Cucurbitacin D could be used as a useful
compound to treat adriamycin-resistant patients.
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Introduction
Breast cancer is the most common cancer for women and is
a major cause of mortality in women [1]. With the devel-
opment of breast cancer therapy, patient survival rates have
greatly improved [2]. Doxorubicin is an anthracycline
antibiotic. Anthracycline antibiotic is one of the natural
product daunomycin and works by intercalating DNA. It is
widely used in the treatments of several cancers [3].
Therefore, doxorubicin is a very important part of a breast
cancer therapy regimen and is a generally used agent [4, 5].
However, doxorubicin drug resistance appears in nearly
50 % of treated patients [6]. And doxorubicin induces an
upregulation of activated Stat3 and NF-jB activation [7,
8].
Stat3 is a predictive marker of drug resistance [9]. Stat3
was significantly overexpressed in doxorubicin-resistant
cells. Thus, Stat3 activation is effective for tumor cell
evasion of cancer therapy.
The NF-jB family contains five members: RelA/p65,
RelB, c-Rel, p50 (NF-jB1), and p52 (NF-jB2). NF-jB is a
dimer composed of p65 and p50. In the cytosol, NF-jB is
inactive through interactions with the inhibitor of NF-jB
proteins. Exposure to a variety of stimuli leads to phos-
phorylation of IKKa, IKKb, and NEMO. Phosphorylated
IjBa is ubiquitinated and degraded by the proteasome;
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then, NF-jB p65 protein is phosphorylated by IKK, and
then translocated into the nucleus [10, 11]. Activation of
NF-jB promotes proliferation, inflammation, and tumori-
genesis in cancer [12, 13].
Signal transducers and activators of transcription (Stat)
proteins comprise a seven-member family of transcription
factors (Stats 1, 2, 3, 4, 5a, 5b, and 6). Stats transduces
signal from extracellular stimulus to the transcription of
target genes. Among the Stats, Stat3 is the most widely
related with tumor development [14]. Stat3 is activated by
phosphorylation of a single tyrosine residue located at
position 705 [15]. Stat3 activation in tumor cells is asso-
ciated with cell proliferation, cell survival, invasion,
angiogenesis, and metastasis. Recently, the Stat3 signaling
pathway has been shown to confer resistance to
chemotherapy-induced apoptosis in human tumors [16–19].
Cucurbitacins are a group of triterpenoids isolated from
plant families Cucurbitaceae and Cruciferae. Cucurbitacins
have anti-inflammatory activity and anti-cancer effects on
various tumors [20]. Cucurbitacins B, D, E, I, F, O, P, and
Q are known to suppress proliferation of tumor cells
through inhibition of STAT3 phosphorylation [21].
Recently, it was reported that cucurbitacin D from Tri-
chosanthes kirilowii has the ability to induce apoptosis in
cancer. Cucurbitacin D impedes Stat3 and NF-jB nuclear
translocation. Cucurbitacin suppresses cell growth and
produces apoptosis in various cancer cell lines [22, 23].
However, the effect of cucurbitacin D has not been
investigated in breast cancer cells.
Stat3 and NF-jB signaling pathways play a critical role
in cancer cells. Additionally, activated p-NF-jB and
p-Stat3 interaction increased intercellular adhesion levels,
migration, and invasion [24, 25]. Thus, Stat3 and NF-jB
decreases are very important in cancer therapy. It is known
that cucurbitacin D suppresses STAT3 and NF-jB activity
inhibiting their nuclear translocation and transcriptional
activity [22, 26]. In the present study, we examined whe-




Cucurbitacin D was purchased from Extrasynthese (Genay
Cedex, France). DMSO and MTT were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Propidium iodide
(PI) was purchased from Invitrogen (Carlsbad, CA, USA).
Annexin V, Alexa Fluor 488 conjugate was obtained from
Life Technologies (Eugene, OR, USA). The antibodies
against cleaved caspase-8, -3, p-STAT3 (Try705), p-IjB
(Ser32/36), p-NF-jB p65 (Ser536), pro-caspase-3, and
total STAT3 were obtained from Cell Signaling (Danvers,
MA, USA). The antibodies against IKK, PARP/p85,
p-IKK, and total NF-jB were obtained from Santa Cruz
Biotechnology (Dallas, Texas, USA). IjB antibody was
obtained from Millipore. Tubulin antibody was obtained
from Sigma-Aldrich (St. Louis, MO, USA). ABC kit and
diaminobenzidine tetrachloride (DAB) were obtained from
Vector (Burlingame, CA, USA).
Cell culture
MCF7 is a breast cancer cell line. MCF7/ADR cells have
been widely used as a multidrug-resistant breast cancer cell
model. MCF7/ADR cells and MCF7 breast cancer cells
obtained from American-Type Culture Collection were
maintained in RPMI1640 supplemented with 10 % heat-
inactivated fetal bovine serum (Invitrogen, Carlsbad, CA,
USA) and 100 U/mL antibiotic–antimycotic (Invitrogen).
Cells were maintained at 37 C in a humidified incubator
with 5 % CO2.
Cell viability assay
Cell viability was measured using the MTT assay. Cells
were plated in 96-well flat bottom tissue culture plates at a
density of 3 9 103 cells/well and incubated for 24 h. Cells
were cultured for an additional 24 h with cucurbitacin D
(0.125–16 lg/mL) or doxorubicin (0.04–25 lM). After
incubation, MTT reagents (0.5 mg/mL) were added to each
well, and the plates were incubated in the dark at 37 C for
another 2 h. The medium was removed, the formazan was
dissolved in DMSO, and the optical density was measured
at 570 nm using an ELISA plate reader.
Nuclear and cytoplasmic fractionation
Adherent cells were washed twice with phosphate-buffered
saline (PBS), and then collected by scraping and pelleted
by centrifugation. Cells were then transferred into a pre-
chilled microcentrifuge tube and gently resuspended in
150 lL hypotonic buffer (20 mM Tris–HCl, pH 7.4,
10 mM NaCl, 3 mM) by pipetting up and down several
times. Cells were incubated on ice for 15 min, and the
homogenates were centrifuged for 10 min at 3000 rpm at
4 C. The supernatants, which contained the cytoplasmic
fraction, were transferred and saved. Nuclear pellets were
resuspended in 500 lL complete cell extraction buffer
(100 mM Tris pH 7.4, 2 mM sodium orthovanadate,
100 mM NaCl, 1 % Triton X-100, 1 mM EDTA, 10 %
glycerol, 1 mM EGTA, 0.1 % SDS, 1 mM sodium fluo-
ride, 0.5 % deoxycholate, 20 mM sodium pyrophosphate
tetrabasic, 1 mM PMSF, protease inhibitor, and dithio-
threitol), and incubated on ice for 30 min with vortexing at
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10 min intervals. The homogenates were centrifuged for
30 min at 14,000 rpm at 4 C. The supernatants (nuclear
fraction) were transferred to a clean microcentrifuge tube,
and then aliquoted and stored at -80 C for further assay.
Western blot analysis
Cells were harvested, incubated in one volume of lysis
buffer (50 mM Tris–Cl pH 7.4, 1 % NP-40, 0.25 % sodium
deoxycholate, 0.1 % SDS, 150 mM NaCl, 1 mM EDTA,
and protease inhibitor) for 20 min and centrifuged at
13,000 rpm at 4 C for 20 min. Aliquots containing 20 lg
of protein were separated by SDS-polyacrylamide gel
electrophoresis using 8–12 % gels and transferred to
nitrocellulose membranes (Protran nitrocellulose mem-
brane, Whatman, UK). Membranes were blocked with 5 %
nonfat milk and probed with specific primary antibodies.
Membranes were then incubated with horseradish peroxi-
dase-conjugated secondary IgG antibody (Calbiochem, San
Diego, CA, USA) and visualized using the enhanced
Fig. 1 Effect of doxorubicin, cucurbitacin D, and doxorubicin with
cucurbitacin D on MCF7 and MCF7/ADR cell viability. MCF7 and
MCF7/ADR cells were treated with different concentrations of
doxorubicin, cucurbitacin D, cucurbitacin D (0.5, 2 lg/mL), and
doxorubicin (1 lM) for 24, 48, and 72 h. Cell viability was then
measured using the MTT assay. Each value represents the
mean ± SD. All data are p\ 0.0001 by Student t-test
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chemiluminescence detection system (Amersham ECL kit,
Amersham Pharmacia Biotech, Inc., Piscataway, NJ,
USA).
Flow cytometric analysis
Flow cytometry was used to analyze cell cycle distribution
and apoptosis. Cells were seeded in 60-mm dishes. After
24 h, cells were cultured for an additional 24 h in the
absence (control) or presence of doxorubicin (1 lM) and/or
cucurbitacin D (0.5 or 2 lg/mL). Trypsinized cells were
washed with PBS and fixed in 95 % ethanol containing
0.5 % Tween-20 overnight at -20 C. After washing with
PBS, cells were then incubated with 1 U/mL of RNase A
and 10 lg/mL of PI for 30 min at room temperature in the
dark. The DNA content in each cell nucleus was deter-
mined by a FACScalibur flow cytometer (Becton–Dickin-
son, San Jose, CA, USA), and the cell cycle was analyzed
using ModFit LT V2.0 software.
Fig. 2 Cucurbitacin D suppresses p-Stat3 expression in MCF7/ADR
Cells. Constitutive activation of Stat3 was detected in MCF7/ADR
cells. p-STAT3 was strongly expressed in MCF7/ADR cells. a Dox-
orubicin increases constitutive STAT3 phosphorylation in a time-
dependent manner in MCF7 cells. b Cucurbitacin D inhibits p-Stat3
expression in MCF7/ADR cells. c Whole-cell lysates were analyzed
by Western blot with anti-pStat3, anti-Stat3, and anti-tubulin
antibodies
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Annexin V-FITC apoptosis assay
Cells were cultured in 60-mm dishes. After 24 h, cells were
cultured for an additional 24 h in the absence (control) or
presence of doxorubicin (1 lM) and/or cucurbitacin D (0.5
or 2 lg/mL). Apoptosis assay was performed with an
Annexin V-FITC/PI double staining apoptosis detection kit
using a flow cytometer following the manufacturer’s
instruction.
Transfection and luciferase assay
For the assay, MCF7/ADR cells were plated and allowed to
attach by overnight incubation. The next day, the cells were
transfected with control Renilla RNA (Qiagen, Venlo,
Netherlands) and STAT3 CA RNA (Santa Cruz, CA, USA)
in the presence of a STAT3-luciferase reporter using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The
cells were then treated with doxorubicin or cucurbitacin D
for 6 h. Luciferase assays were performed using a dual-
luciferase assay kit (Promega, Madison, WI, USA)
according to the manufacturer’s instructions. Briefly, cells
were lysed using a passive lysis buffer. Cell lysates were
then centrifuged, and the supernatant was saved for anal-
ysis. Finally, luciferase activities were determined using a
luminometer (BMG Labtech, Ortenberg, Germany).
Immunocytochemical analysis
MCF7/ADR cells were inoculated at a density of 3 9
104 cells per well in eight-well chamber slides (BD Falcon,
Bedford, MA). The next day, the cells were treated with
cucurbitacin D or doxorubicin for 6 h. The cells were fixed
with 4 % paraformaldehyde for 30 min and treated with
3 % hydrogen peroxide (H2O2) in methanol for 20 min to
quench the endogenous peroxidase activity. The cells were
washed with PBS, blocked with 5 % BSA in PBS for 1 h
and incubated with the anti-NF-jB and anti-STAT3 pri-
mary antibody (1:100 dilution) overnight at 4 C. After
washing with PBS, the cells were incubated with the anti-
rabbit biotin-conjugated secondary antibody for 1 h at
room temperature. Then, the cells were treated with Vec-
tastain ABC reagent (Vector Laboratories, Inc., Burlin-
game, CA, USA) for 30 min at 4 C and stained with DAB
and hematoxylin. The cells were mounted with mounting
medium and subsequently analyzed by microscopy.
Statistical analysis
The results of all experiments were expressed as the
mean ± standard deviation (SD) of at least three separate
tests. A Student’s t-test was used for single-variable
Fig. 3 Cucurbitacin D inhibits NF-jB signaling in MCF7/ADR cells.
MCF7/ADR cells were treated with cucurbitacin D (0.5, 2 lg/mL) in
the presence and absence of doxorubicin (1 lM). Nuclear and
cytosolic extracts of cultured cells were then prepared and analyzed
by Western blot to measure NF-jB levels
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Fig. 4 Cucurbitacin D inhibits nuclear translocation of Stat3 and NF-
jB in MCF7/ADR cells. MCF7/ADR cells were treated with
cucurbitacin D (0.1 lg/mL) in the presence and absence of doxoru-
bicin (1 lM), and then submitted to immunocytochemistry for the
detection of nuclear NF-jB (a) and Stat3 (b)
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comparisons, and a p value\0.05 was considered statisti-
cally significant.
Results
Effect of doxorubicin, cucurbitacin D,
and doxorubicin with cucurbitacin D on MCF7
and MCF7/ADR cell viability
We investigated whether doxorubicin, cucurbitacin D, and
doxorubicin with cucurbitacin D affected the cell viability
of MCF7 and MCF7/ADR cells.
For that purpose, both MCF7 and MCF7/ADR cells
were treated with different concentrations of doxorubicin
(0.04, 0.2, 1, 5, and 25 lM) for 24–72 h. Cell viability was
then measured by MTT assay. We found that doxorubicin
significantly suppressed cell growth in a dose- and time-
dependent manner in MCF7. However, doxorubicin failed
to decrease cell viability in MCF7/ADR cells (Fig. 1a, b).
Both MCF7 and MCF7/ADR cells were treated with dif-
ferent concentrations of cucurbitacin D (0.125, 0.5, 2, 4, 8,
and 16 lg/mL) for 24–72 h. We found that cucurbitacin D
significantly suppressed cell growth in both MCF7 and
MCF7/ADR in a dose- and time-dependent manner
(Fig. 1c, d). We co-treated MCF7 and MCF7/ADR cells
with doxorubicin (1 lM) and cucurbitacin D (0.5, 2 lg/mL)
to investigate whether cucurbitacin D overcomes doxoru-
bicin resistance. We found that cucurbitacin D and dox-
orubicin significantly suppressed cell growth in MCF7 cells,
and cucurbitacin D reversed the doxorubicin-resistant cell
growth of the MCF7/ADR cell line (Fig. 1e, f).
Cucurbitacin D suppresses Stat3 expression
in MCF7/ADR cells
To determine the relationship between Stat3 and doxoru-
bicin resistance in human breast cancer cells, we analyzed
the expression of p-STAT3 and Stat3 in MCF7/ADR cells
and MCF7 cells. We found that p-Stat3 expression was
significantly overexpressed in MCF7/ADR cells than in the
MCF7 cell line (Fig. 2a). Next, we determined whether
doxorubicin increased p-Stat3 expression in MCF7 cells.
We found that doxorubicin alone increased p-STAT3 level
in a time-dependent manner (Fig. 2b).
To further characterize the Stat3-inhibitory effect of
cucurbitacin D and doxorubicin in MCF7/ADR cells, we
found that cucurbitacin D decreased p-STAT3 level in the
absence and presence of doxorubicin, suggesting that
cucurbitacin D inhibits STAT3 signaling in MCF7/ADR
cells (Fig. 2c).
Cucurbitacin D inhibits the NF-jB signaling
pathway in MCF7/ADR cells
We investigated whether cucurbitacin D inhibits NF-jB
signaling in MCF7/ADR cells. For that purpose, we treated
MCF7/ADR cells with cucurbitacin D (0.5, 2 lg/mL) and/
or doxorubicin (1 lM), and we prepared nuclear and
cytosolic fractions of the treated cells subjected them to
Western blot analysis. We found that cucurbitacin D
increased IjB and NF-jB expression levels in the cytosol
and decreased p-NF-jB level in the nucleus (Fig. 3a, b).
Cucurbitacin D suppresses Stat3 and NF-jB
translocation in MCF7/ADR cells
To confirm that cucurbitacin D inhibits nuclear transloca-
tion of Stat3 and NF-jB, we performed immunocyto-
chemistry on MCF7/ADR cells. We found that
cucurbitacin D marked cytosol presence of STAT3 and NF-
jB and decreased nuclear staining of NF-jB (Fig. 4a) and
Stat3 (Fig. 4b) in MCF7/ADR cells. This suggests that
cucurbitacin D inhibits nuclear translocation of Stat3 and
NF-jB.
Cucurbitacin D suppresses Stat3 and NF-jB
transcriptional activity
Although cucurbitacin D inhibits Stat3 and NF-jB
translocation ability, it is not known whether the compound
can regulate Stat3 and NF-jB transcriptional activity.
Therefore, we performed luciferase reporter gene assays to
detect Stat3 and NF-jB transcriptional activity. We found
that cucurbitacin D significantly repressed STAT3 and NF-
jB transcription activity in MCF7 cells (Fig. 5a, b).
Cucurbitacin D induces apoptosis and G2/M cell
cycle arrest in MCF7/ADR cells
To investigate whether cucurbitacin D inhibits cell prolif-
eration by promoting changes in cell cycle progression, the
effect of cucurbitacin D on the cell cycle profile was
assessed using flow cytometry. For this purpose, MCF7/
ADR cells were treated with cucurbitacin D (0.5 lg/mL)
and/or doxorubicin (1 lM) for 24 h. The results demon-
strated that cucurbitacin D induced an increase in the sub-
G1 and G2/M populations in MCF7/ADR cells, suggesting
that cucurbitacin D induces G2/M cell cycle arrest
(Fig. 6a). We found that doxorubicin did not induce
apoptosis in drug-resistant cells; however, cucurbitacin D
treatment resulted in a 114 % increase in apoptosis
(apoptotic cells were calculated after Annexin V/PI stain-
ing) when compared to that of control group. Doxorubicin
with cucurbitacin D treatment resulted in a 145 % increase
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in apoptosis (apoptotic cells were calculated after Annexin
V/PI staining) when compared to that of doxorubicin
control group (Fig. 6b). Because the sub-G1 level was
increased by cucurbitacin D treatment, we performed
Annexin V/PI staining flow cytometry analysis to detect
apoptotic cells. To confirm that caspase activation is
involved in cucurbitacin D-induced apoptosis in MCF7/
ADR cells, we found that cucurbitacin D up-regulated the
levels of cleaved caspase-3, cleaved caspase-8, and cleaved
PARP in MCF7/ADR cells (Fig. 6c).
Discussion
In this study, we found that cucurbitacin D decreased cell
proliferation and induced apoptosis by inhibiting Stat3 and
NF-jB signaling in doxorubicin-resistant breast cancer
cells, MCF7/ADR.
Among the Stat proteins, persistent activation of Stat3 is
detected in human cancer cell lines and tumor tissues [24,
25]. These include breast cancer, lung cancer, pancreatic
cancer, head and neck cancer, prostate cancer, ovarian
cancer, melanoma, leukemias, and lymphomas. Stat3
activation in tumor cells is associated with cell prolifera-
tion, cell survival, invasion, angiogenesis, and metastasis
[27]. Doxorubicin-treated cancer cells contained activated
Stat3. Stat3 activation is linked to the development of
doxorubicin resistance in cancer cell lines [28]. Stat3 is a
predictive marker of drug resistance [9]. Therefore, we
analyzed the expression and activation of Stat3 in MCF7
and doxorubicin-resistant MCF7/ADR cells. We also
investigated whether Stat3 activation was associated with
doxorubicin resistance in MCF7/ADR. We found that Stat3
was constitutively activated in MCF7/ADR, and this acti-
vation was disrupted by cucurbitacin D. This result sug-
gests that cucurbitacin D inhibits cell growth and induces
apoptosis by inhibiting Stat3 signaling. Additionally,
cucurbitacin D inhibits nuclear translocation of Stat3, as
revealed by immunocytochemistry.
NF-jB has an important effect on cell growth and
inhibition of apoptosis. Activation of NF-jB promotes
proliferation, inflammation, and tumorigenesis in cancer
[12–14]. To investigate the mechanism by which cucur-
bitacin D decreases cell growth and induces apoptosis in
MCF7/ADR cells, we made nuclear and cytosolic fractions
and analyzed them by Western blot to measure the levels of
NF-jB signaling molecules. We found that cucurbitacin D
increased IjB level in the cytosol and suppressed the
nuclear translocation of p-NF-jB, resulting in apoptosis.
Cucurbitacin D suppressed cell growth in both MCF7 and
MCF7/ADR cells in a dose- and time-dependent manner.
This growth inhibition was accompanied by cell mor-
phology changes and cell cycle arrest. The cell cycle is
controlled by numerous mechanisms ensuring correct cell
division. Additionally, cancer progression is related to
aberrant cell cycle regulation [29]. G2/M DNA damage
checkpoint consists of an arrest of the cell in G2 just before
mitotic entry in response to genotoxic stress [30]. We
found that cucurbitacin D increases the sub-G1 population
and G2/M population in MCF7/ADR cells. To confirm
apoptosis, we performed the Annexin V-FITC/PI assay and
Fig. 5 Cucurbitacin D inhibits Stat3 and NF-jB transcription in
MCF7 cells. MCF7 cells were transfected with the indicated siRNA
or plasmid, and then treated with each drug for 24 h. MCF7 cells were
then treated with cucurbitacin D (0.5 lg/mL). Afterward, lysates were
analyzed using the dual-luciferase reporter assay. Each value
represents the mean ± SD. All data are p\ 0.0001 by Student t-test
cFig. 6 Cucurbitacin D induces G2/M cell cycle arrest and apoptosis
in MCF7/ADR cells. MCF7/ADR cells were treated with cucurbitacin
D (0.5 lg/mL) in the presence and absence of doxorubicin (1 lM) for
24 h. Cell cycle distribution was analyzed using a FACS flow
cytometer (a). MCF7/ADR cells were treated with the indicated drugs
for 24 h and subjected to Annexin V/PI assay. b Effect of
cucurbitacin D on the expression of cleaved caspase-3, cleaved
caspase-8, and cleaved PARP. MCF7/ADR cells were treated with
cucurbitacin D (0.5 lg/mL) in the presence and absence of doxoru-
bicin (1 lM) for 24 h. The cell lysates were subjected to Western blot
analysis using specific antibodies (c)
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Western blot in MCF7/ADR cells. Cucurbitacin D treat-
ment resulted in a 114 % increase in apoptosis when
compared to that of control group. Additionally, results of
Western blots demonstrate that cucurbitacin D up-regu-
lated the levels of cleaved caspase-3, cleaved caspase-8,
and cleaved PARP. Thereby, cucurbitacin D obviously
induces apoptosis in MCF7/ADR cells. Because
cucurbitacin D inhibits cell growth and induces apoptosis
in doxorubicin-resistant breast cancer cells, MCF7/ADR,
cucurbitacin D could be used as a useful compound to treat
drug resistance. Targeting Stat3 and NF-jB may also be
useful to treat breast cancer. Our study clearly demon-
strates that cucurbitacin D overcomes doxorubicin resis-
tance in breast cancer cells.
Fig. 6 continued
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Conclusions
These results clearly demonstrate that cucurbitacinD could be
used as a useful compound to overcome doxorubicin
resistance.
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